Five pharma companies fine-tuned OpenFold3 Preview 2 across 20,167 private structures, none of which left their environments. On 1,056 held-out structures, high-quality interface predictions rose from 35.6% to 52.1% and correct ligand poses from 28.9% to 46.8%, ahead of every public model. A first for federated drug discovery.
